| DC73078 |
TKB248 |
TKB248 (TKB-248) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 74 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.22 and 0.87 µM, respectively. |
|
| DC73079 |
VE607 |
VE607 is a specific small molecule inhibitor that block S protein-ACE2-mediated cellular entry of the SARS-CoV, inhibits pseudovirus entry with EC50 of 3 μM and inhibited SARS-CoV plaque formation with EC50 of 1.6 μM. |
|
| DC73080 |
WNN2048-F004 |
WNN2048-F004 (Compound 4a) is a potent, covalent, nonpeptidomimetic SARS-CoV-2 main protease (Mpro) inhibitor with biochemical IC50 of 103 nM, covalently binds to the substrate-binding pocket (Cys145) of SARS-CoV-2 Mpro. |
|
| DC73081 |
WU-04 |
WU-04 is a highly potent, non-covalent, orally active inhibitor of SARS-CoV-2 3C-like protease (3CLpro) with IC50 of 72 nM, binding Kd of 37 nM. |
|
| DC73082 |
Y180 |
Y180 is a highly potent, selective, covalent, and orally active SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 8.1 nM in enzymatic assays, binding Ki value of 1 nM. |
|
| DC73083 |
Z222979552 |
Z222979552 is a small molecule non-covalent SARS-CoV-2 Mpro inhibitor with IC50 of 1.0 uM. |
|
| DC73084 |
Z8539_0072 |
Z8539_0072 is a potent SARS-CoV-2 macrodomain inhibitor that binds to the NSP3 macrodomain of SARS-CoV-2 (Mac1) with IC50 of 460 nM. |
|
| DC73085 |
ANP0903 |
ANP0903 is an analog of HIV-1 protease inhibitor darunavir, induces cytotoxicity in hepatocellular carcinoma cell lines, triggers apoptosis by enhancing ER stress. |
|
| DC73086 |
Tpz-1 |
Tpz-1 is a unique cytotoxic compound that elicits potent and selective programmed cell death in human blood, breast, colon, and cervical cancer cell lines, interferes with components of signaling pathways and the cytoskeleton that are important to cell sh |
|
| DC73087 |
WZY-321 |
WZY-321 a small molecule glioma cell apoptosis inducer, binds to XAF1 3-UTR and decreases XAF1 (X-linked inhibitor of apoptosis-associated factor 1) mRNA levels. |
|
| DC73088 |
BAU-243 |
BAU-243 (BAU243) is a novel BH3 mimetic Bcl-2 inhibitor with a high affinity, effectively reduces overall GBM cell proliferation including a subpopulation of cancer-initiating cells. |
|
| DC73089 |
BDM44898 |
BDM44898 is a small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 1.6 uM. |
|
| DC73090 |
BDM44931 |
BDM44931 is a small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 1.3 uM. |
|
| DC73091 |
BDM49234 |
BDM49234 is a selective small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 6.3 uM (inhibition FITC–Bim BH3 binding to Bfl-1). |
|
| DC73092 |
BDM53787 |
BDM53787 is a selective small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 0.8 uM (inhibition FITC–Bim BH3 binding to Bfl-1). |
|
| DC73093 |
BI-5273 |
BI-5273 is a negative control compound of BI-3802 and BI-3812, which are potent and efficacious BCL6 degrader and inhibitor, respectively. |
|
| DC73094 |
CCT372064 |
CCT372064 is a potent, ligand-efficient inhibitor of BCL6 with IC50 of 3.9 nM and 12 nM in TR-FRET and cellular NanoBRET assays, respectively. |
|
| DC73095 |
CCT373566 |
CCT373566 is a highly potent, in vivo active BCL6 degarder with IC50 of 2.2 nM and DC50 of 0.7 nM in TR-FRET and cellular BCL6 degradation assays, respectively. |
|
| DC73096 |
CCT373567 |
CCT373567 is a potent, selective and cell-active BCL6 inhibitor with IC50 of 2.9 nM in TR-FRET assays, and 25.9 nM in NanoBRET cellular inhibition assays. |
|
| DC73097 |
CCT374705 |
CCT374705 is a potent, selective, in-vivo active BCL6 inhibitor with TR-FRET IC50 of 6 nM. |
|
| DC73098 |
CGDF-183-20 |
CGDF-183-20 is a selective small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 264 nM in FP assays. |
|
| DC73099 |
CGDF-190-20 |
CGDF-190-20 is a selective small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 365 nM in FP assays. |
|
| DC73100 |
DC-B01 |
DC-B01 is a novel small molecule BCL-2 inhibitor that binds to the BH4 domain with KD of 2.16 uM, disrupts the BCL-2/c-Myc interaction and consequently suppresses the transcriptional activity of c-Myc. |
|
| DC73101 |
GSK137 |
GSK137 is a potent, small-molecule BCL6 inhibitor binding to BCL6 BTB-POZ domain, displaces peptides derived from the human SMRT co-repressor from the BCL6 BTB-POZ domain in a TR-FRET assay with a pIC50 of 8.0. |
|
| DC73102 |
M109S |
M109S is a small molecule protecting cells from mitochondria-dependent apoptosis wtih EC50 of 23.4 nM in iBax cells, directly interacts with Bax (Kd=153 nM, MST assay) and inhibits Bax activation. |
|
| DC73103 |
MI-238 |
MI-238 (MI 238) is a potent and specific Mcl-1 inhibitor with Ki of 0.45 uM to human Mcl-1 protein in FP assays, disrupts the association of Mcl-1 with BH3-only proteins. |
|
| DC73104 |
Obatoclax |
A potent inhibitor of Bcl-2 family with IC50s of 1-7 uM for Bcl-2, Bcl-XL, Bcl-w, Bcl-B, Mcl-1 and Bfl-1. |
|
| DC73105 |
OICR12694 |
OICR12694 (OICR 12694, JNJ-65234637) is a potent, selective, and orally bioavailable BCL6-BTB inhibitor with SPR KD value of 5 nM. |
|
| DC73106 |
Sonrotoclax |
Sonrotoclax (BGB-11417) is a potent, selective and second-generation BCL2 inhibitor with IC50 of 0.014 nM and SPR KD value of 0.046 nM, overcomes BCL2 G101V mutation-induced venetoclax resistance. |
|
| DC73107 |
WK369 |
WK369 (WK-369) is a specific small molecule inhibitor of BCL6, directly binds to the BCL6-BTB domain (SPR KD=2.24 uM) and blocks the interaction between BCL6 and SMRT with IC50 of 0.32 uM in HTRF assays. |
|
